RXi Pharmaceuticals Corp. (RXII)

3.22
NASDAQ : Health Technology
Prev Close 3.20
Day Low/High 3.14 / 3.70
52 Wk Low/High 2.91 / 11.20
Avg Volume 269.50K
Exchange NASDAQ
Shares Outstanding 2.37M
Market Cap 7.63M
EPS -16.40
Div & Yield N.A. (N.A)

Latest News

RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth

RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth

-- Company to capitalize on proprietary self-delivering RNAi platform (sd-rxRNA®) that has now been proven to be safe and effective in clinical trials

RXi Pharmaceuticals Announces Positive Results From Phase 2 Trial With RXI-109 For Dermal Scarring

RXi Pharmaceuticals Announces Positive Results From Phase 2 Trial With RXI-109 For Dermal Scarring

- RXI-109 is a self-delivering RNAi (sd-rxRNA) compound that targets connective tissue growth factor (CTGF), a key regulator of fibrosis and scar formation, and plays a key role in tissue regeneration and repair.

Medigene Collaborates With RXi Pharmaceuticals To Further Sharpen Its Therapeutic T Cells

Medigene Collaborates With RXi Pharmaceuticals To Further Sharpen Its Therapeutic T Cells

- Synergies between the recombinant T cell technologies of Medigene and self-delivering RNAi technologies from RXi Pharmaceuticals will be explored preclinically

RXi Pharmaceuticals And The Center For Cancer Immune Therapy At Herlev Hospital Announce Research Collaboration

RXi Pharmaceuticals And The Center For Cancer Immune Therapy At Herlev Hospital Announce Research Collaboration

The Center for Cancer Immune Therapy at Herlev Hospital, University of Copenhagen, is a leading European cancer center that received a Global Excellence Award in 2013 from the Capital Region of Denmark

RXi Pharmaceuticals Announces Positive Results With RXI-231 In Consumer Testing Program

RXi Pharmaceuticals Announces Positive Results With RXI-231 In Consumer Testing Program

RXI-231 is a cosmetic ingredient in a proprietary gel formulation designed to aid in the reduction of pigmentation to improve skin appearance

RXi Pharmaceuticals Announces The Departure Of Dr. Alexey Eliseev As Chief Business Officer

RXi Pharmaceuticals Announces The Departure Of Dr. Alexey Eliseev As Chief Business Officer

Dr. James Cardia, RXi's Director of Business Development and Intellectual Property, will take over the management of the Company's ongoing business development and partnering initiatives

BioAxone BioSciences Awarded NINDS SBIR Funding For The Development Of Self-Delivering RNAi (sd-rxRNA®) For The Treatment Of Spinal Cord Injury

BioAxone BioSciences Awarded NINDS SBIR Funding For The Development Of Self-Delivering RNAi (sd-rxRNA®) For The Treatment Of Spinal Cord Injury

RXi Pharmaceuticals is a collaborator on this grant and will receive a portion of the allotted funding for the development of sd-rxRNA therapeutic compounds targeting PTEN

RXi Pharmaceuticals Corporation Selected To Present At The 8th Annual Investing For Cures Forum

RXi Pharmaceuticals Corporation Selected To Present At The 8th Annual Investing For Cures Forum

The forum brings together leading family offices, high net worth private investors, pharma and foundations to explore the latest innovations transforming healthcare.

RXi Pharmaceuticals Announces Completion Of Enrollment Of Phase 1/2 Clinical Trial With RXI-109 For Retinal Scarring

Study RXI-109-1501 is evaluating the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases

RXi Pharmaceuticals Announces The Initiation Of Its Consumer Testing Program With RXI-231

RXI-231 is in development as a cosmetic ingredient that may improve the appearance of uneven skin tone and pigmentation